恶性腹水与前列腺癌相关。

The journal of applied research Pub Date : 2005-01-01
Muhammad Wasif Saif
{"title":"恶性腹水与前列腺癌相关。","authors":"Muhammad Wasif Saif","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>BACKGROUND: Prostate cancer is the most common malignancy in men in the United States. Both at diagnosis and throughout the disease progression, it can metastasize to multiple organs, most commonly bone and lymph nodes. Effusions (either pleural or abdominal) are relatively uncommon. PATIENTS AND METHODS: We reviewed the medical literature including the case reports and post-mortem studies relating ascites to prostate cancer, identified through a MEDLINE search (human; all languages; 1969-2004). RESULTS: We found 12 published cases. Forty two percent of patients presented initially with ascites, in 50% ascites developed later with progressive disease, and 8% had ascites being the only site of recurrence. The response rate to endocrine therapy, including orchiectomy, was 25%. Ascites in these patients conferred a poorer prognosis. CONCLUSION: The development of ascites secondary to prostate cancer, either as an initial manifestation or recurrent disease, is not well known and may be unfamiliar to many physicians. If patients with history of prostate cancer develop malignant effusions, prostate specific antigen (PSA) immunohistostaining of the fluid can serve as a valuable adjunctive study for the diagnosis. This clinical situation becomes particularly important in patients with ascites with a carcinoma of unknown primary. Palliation can be achieved in patients with ascites secondary to prostate cancer using hormone manipulation. Lack of knowledge about this complication of prostate cancer may delay the diagnosis and treatment of this hormonally responsive malignancy.</p>","PeriodicalId":88162,"journal":{"name":"The journal of applied research","volume":"5 2","pages":"305-311"},"PeriodicalIF":0.0000,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835369/pdf/nihms145064.pdf","citationCount":"0","resultStr":"{\"title\":\"Malignant Ascites Associated with Carcinoma of the Prostate.\",\"authors\":\"Muhammad Wasif Saif\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>BACKGROUND: Prostate cancer is the most common malignancy in men in the United States. Both at diagnosis and throughout the disease progression, it can metastasize to multiple organs, most commonly bone and lymph nodes. Effusions (either pleural or abdominal) are relatively uncommon. PATIENTS AND METHODS: We reviewed the medical literature including the case reports and post-mortem studies relating ascites to prostate cancer, identified through a MEDLINE search (human; all languages; 1969-2004). RESULTS: We found 12 published cases. Forty two percent of patients presented initially with ascites, in 50% ascites developed later with progressive disease, and 8% had ascites being the only site of recurrence. The response rate to endocrine therapy, including orchiectomy, was 25%. Ascites in these patients conferred a poorer prognosis. CONCLUSION: The development of ascites secondary to prostate cancer, either as an initial manifestation or recurrent disease, is not well known and may be unfamiliar to many physicians. If patients with history of prostate cancer develop malignant effusions, prostate specific antigen (PSA) immunohistostaining of the fluid can serve as a valuable adjunctive study for the diagnosis. This clinical situation becomes particularly important in patients with ascites with a carcinoma of unknown primary. Palliation can be achieved in patients with ascites secondary to prostate cancer using hormone manipulation. Lack of knowledge about this complication of prostate cancer may delay the diagnosis and treatment of this hormonally responsive malignancy.</p>\",\"PeriodicalId\":88162,\"journal\":{\"name\":\"The journal of applied research\",\"volume\":\"5 2\",\"pages\":\"305-311\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835369/pdf/nihms145064.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The journal of applied research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of applied research","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:前列腺癌是美国男性最常见的恶性肿瘤。在诊断和整个疾病进展过程中,它可以转移到多个器官,最常见的是骨和淋巴结。积液(胸腔或腹腔)相对少见。患者和方法:我们回顾了医学文献,包括病例报告和前列腺癌相关的死后研究,通过MEDLINE检索(人类;所有的语言;1969 - 2004)。结果:共找到12例已发表病例。42%的患者最初表现为腹水,50%的患者随着疾病的进展而发展,8%的患者腹水是唯一复发的部位。内分泌治疗(包括睾丸切除术)的有效率为25%。腹水患者预后较差。结论:前列腺癌继发腹水的发展,无论是作为初始表现还是复发性疾病,都不为人所知,对许多医生来说可能是陌生的。如果有前列腺癌病史的患者出现恶性积液,前列腺特异性抗原(PSA)免疫组织染色可作为有价值的辅助诊断研究。这种临床情况在原发不明的腹水患者中尤为重要。在前列腺癌继发腹水患者中,使用激素操作可以达到缓解。缺乏对前列腺癌并发症的了解可能会延误这种激素反应性恶性肿瘤的诊断和治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Malignant Ascites Associated with Carcinoma of the Prostate.

BACKGROUND: Prostate cancer is the most common malignancy in men in the United States. Both at diagnosis and throughout the disease progression, it can metastasize to multiple organs, most commonly bone and lymph nodes. Effusions (either pleural or abdominal) are relatively uncommon. PATIENTS AND METHODS: We reviewed the medical literature including the case reports and post-mortem studies relating ascites to prostate cancer, identified through a MEDLINE search (human; all languages; 1969-2004). RESULTS: We found 12 published cases. Forty two percent of patients presented initially with ascites, in 50% ascites developed later with progressive disease, and 8% had ascites being the only site of recurrence. The response rate to endocrine therapy, including orchiectomy, was 25%. Ascites in these patients conferred a poorer prognosis. CONCLUSION: The development of ascites secondary to prostate cancer, either as an initial manifestation or recurrent disease, is not well known and may be unfamiliar to many physicians. If patients with history of prostate cancer develop malignant effusions, prostate specific antigen (PSA) immunohistostaining of the fluid can serve as a valuable adjunctive study for the diagnosis. This clinical situation becomes particularly important in patients with ascites with a carcinoma of unknown primary. Palliation can be achieved in patients with ascites secondary to prostate cancer using hormone manipulation. Lack of knowledge about this complication of prostate cancer may delay the diagnosis and treatment of this hormonally responsive malignancy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信